Literature DB >> 31325142

Association analyses reveal gender-specific associations of DAT1 40-bp VNTR and -839C/T polymorphisms with obsessive-compulsive disorder and obsessive-compulsive symptoms.

Juliana C Cotrin1, Leonardo F Fontenelle2,3,4, Fabiana B Kohlrausch5,6.   

Abstract

The dopamine transporter (DAT) is involved in dopamine signaling and distribution, controlling dopamine concentrations and contributing to several central nervous system disorders. The purpose of this study was to determine the association between two functional polymorphisms in DAT1 gene, the 40-base pair Variable Number of Tandem Repeats (VNTR) and the Single Nucleotide Polymorphism (SNP) -839C/T and obsessive-compulsive disorder (OCD) and/or its clinical features. To do so, 199 OCD patients and 201 healthy controls were genotyped using Polymerase Chain Reaction (PCR). Genotype distribution of both polymorphisms was in Hardy-Weinberg equilibrium. Although OCD and controls did not differ in terms of polymorphisms distribution, we observed that the presence of 10R-allele protected men of having OCD (P = 0.03). We also observed a significant association between the presence of 10R and checking in women (P = 0.02; OR = 3.14; 95%CI 1.08-9.11), and between the 9/9 genotype and neutralization in men (P = 0.04; OR = 3.38; 95%CI 1.03-11.11). Finally, the T-allele of -839C/T was significantly associated with the "obsession" score (P = 0.02; OR = 2.66; 95%CI 1.15-6.13). Our results demonstrate an important influence of dopaminergic pathways, particularly DAT1 polymorphisms, in OCD.

Entities:  

Keywords:  Dopamine; OCD; Polymorphism; Symptom dimension, Brazil

Mesh:

Substances:

Year:  2019        PMID: 31325142     DOI: 10.1007/s11033-019-04971-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  71 in total

Review 1.  Toward a neurobiology of obsessive-compulsive disorder.

Authors:  A M Graybiel; S L Rauch
Journal:  Neuron       Date:  2000-11       Impact factor: 17.173

2.  Thalamic deactivation during early implicit sequence learning: a functional MRI study.

Authors:  S L Rauch; P J Whalen; T Curran; S McInerney; S Heckers; C R Savage
Journal:  Neuroreport       Date:  1998-03-30       Impact factor: 1.837

Review 3.  Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective.

Authors:  David L Pauls; Amitai Abramovitch; Scott L Rauch; Daniel A Geller
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

Review 4.  Neurobiology and clinical pharmacology of obsessive-compulsive disorder.

Authors:  J Micallef; O Blin
Journal:  Clin Neuropharmacol       Date:  2001 Jul-Aug       Impact factor: 1.592

5.  Catechol-O-Methyltransferase Gene Polymorphisms in Specific Obsessive-Compulsive Disorder Patients' Subgroups.

Authors:  Fernanda Brito Melo-Felippe; Juliana Braga de Salles Andrade; Isabele Gomes Giori; Tamiris Vieira-Fonseca; Leonardo Franklin Fontenelle; Fabiana Barzotti Kohlrausch
Journal:  J Mol Neurosci       Date:  2015-12-19       Impact factor: 3.444

6.  Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area.

Authors:  Eliyahu Dremencov; Mostafa El Mansari; Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2009-05       Impact factor: 6.186

Review 7.  Genetic susceptibility in obsessive-compulsive disorder.

Authors:  Thomas V Fernandez; James F Leckman; Christopher Pittenger
Journal:  Handb Clin Neurol       Date:  2018

Review 8.  Drug treatment of obsessive-compulsive disorder.

Authors:  Michael Kellner
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

Review 9.  Neuroimaging Studies in Obsessive Compulsive Disorder: A Narrative Review.

Authors:  Arpit Parmar; Siddharth Sarkar
Journal:  Indian J Psychol Med       Date:  2016 Sep-Oct

10.  Disruption in the balance between goal-directed behavior and habit learning in obsessive-compulsive disorder.

Authors:  Claire M Gillan; Martina Papmeyer; Sharon Morein-Zamir; Barbara J Sahakian; Naomi A Fineberg; Trevor W Robbins; Sanne de Wit
Journal:  Am J Psychiatry       Date:  2011-05-15       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.